Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Arcturus Therapeutics Holdings Inc. has received an average rating of "Moderate Buy" from analysts, with one sell recommendation, eight buy recommendations, and one strong buy recommendation.
• The average twelve-month price target among analysts for Arcturus Therapeutics is $50.57.
• Arcturus Therapeutics reported earnings of ($0.34) per share, surpassing the consensus estimate of ($1.11), along with revenue of $28.30 million during the latest quarter.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $50.5714.

A number of equities research analysts have recently issued reports on ARCT shares. Scotiabank restated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Zacks Research upgraded Arcturus Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 13th. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. HC Wainwright assumed coverage on Arcturus Therapeutics in a research report on Thursday, September 4th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Wednesday, October 8th.

Arcturus Therapeutics Stock Up 4.1%

Shares of Arcturus Therapeutics stock opened at $21.51 on Tuesday. Arcturus Therapeutics has a twelve month low of $8.04 and a twelve month high of $23.59. The business has a 50-day moving average price of $19.01 and a 200 day moving average price of $14.68. The firm has a market cap of $584.21 million, a PE ratio of -9.65 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.77. The firm had revenue of $28.30 million during the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. On average, sell-side analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Kennedy Capital Management LLC lifted its stake in Arcturus Therapeutics by 4.9% during the second quarter. Kennedy Capital Management LLC now owns 11,674 shares of the biotechnology company's stock worth $152,000 after purchasing an additional 544 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 738 shares in the last quarter. Tocqueville Asset Management L.P. lifted its stake in Arcturus Therapeutics by 4.5% during the first quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company's stock worth $248,000 after purchasing an additional 1,000 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Arcturus Therapeutics by 9.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock worth $156,000 after purchasing an additional 1,232 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Arcturus Therapeutics by 0.7% in the second quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company's stock valued at $3,805,000 after acquiring an additional 2,098 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.